RATIONALE: Pulmonary arterial hypertension (PAH) related to systemic sclerosis (SSc) has a poorer prognosis compared with other forms of PAH for reasons that remain unexplained. OBJECTIVES: To identify risk factors of mortality in a well-characterized cohort of patients with PAH related to systemic sclerosis (SSc-PAH). METHODS: Seventy-six consecutive patients with SSc (64 women and 12 men; mean age 61 +/- 11 yr) were diagnosed with PAH by heart catheterization in a single center, starting in January 2000, and followed over time. Kaplan-Meier estimates were calculated and mortality risk factors were analyzed. MEASUREMENTS AND MAIN RESULTS: Forty (53%) patients were in World Health Organization functional class III or IV. Mean pulmonary artery pressure was 41 +/- 11 mm Hg, pulmonary vascular resistance (PVR) was 8.6 +/- 5.6 Wood units, and cardiac index was 2.4 +/- 0.7 L/min/m(2). Median follow-up time was 36 months, with 42 deaths observed. Survival estimates were 85%, 72%, 67%, 50%, and 36% at 1, 2, 3, 4, and 5 years, respectively. Multivariate analysis identified PVR (hazard ratio [HR], 1.10; 95% confidence interval [CI], 1.03-1.18; P < 0.01), stroke volume index (HR, 0.94; 95% CI, 0.89-0.99; P = 0.02), and pulmonary arterial capacitance (HR, 0.43; 95% CI, 0.20-0.91; P = 0.03) as strong predictors of survival. An estimated glomerular filtration rate less than 60 ml/min/1.73 m(2) portended a threefold risk of mortality. CONCLUSIONS: Our results suggest that specific components of right ventricular dysfunction and renal impairment contribute to increased mortality in SSc-PAH. Understanding the mechanisms of right ventricular dysfunction in response to increased afterload should lead to improved targeted therapy in these patients.
RATIONALE: Pulmonary arterial hypertension (PAH) related to systemic sclerosis (SSc) has a poorer prognosis compared with other forms of PAH for reasons that remain unexplained. OBJECTIVES: To identify risk factors of mortality in a well-characterized cohort of patients with PAH related to systemic sclerosis (SSc-PAH). METHODS: Seventy-six consecutive patients with SSc (64 women and 12 men; mean age 61 +/- 11 yr) were diagnosed with PAH by heart catheterization in a single center, starting in January 2000, and followed over time. Kaplan-Meier estimates were calculated and mortality risk factors were analyzed. MEASUREMENTS AND MAIN RESULTS: Forty (53%) patients were in World Health Organization functional class III or IV. Mean pulmonary artery pressure was 41 +/- 11 mm Hg, pulmonary vascular resistance (PVR) was 8.6 +/- 5.6 Wood units, and cardiac index was 2.4 +/- 0.7 L/min/m(2). Median follow-up time was 36 months, with 42 deaths observed. Survival estimates were 85%, 72%, 67%, 50%, and 36% at 1, 2, 3, 4, and 5 years, respectively. Multivariate analysis identified PVR (hazard ratio [HR], 1.10; 95% confidence interval [CI], 1.03-1.18; P < 0.01), stroke volume index (HR, 0.94; 95% CI, 0.89-0.99; P = 0.02), and pulmonary arterial capacitance (HR, 0.43; 95% CI, 0.20-0.91; P = 0.03) as strong predictors of survival. An estimated glomerular filtration rate less than 60 ml/min/1.73 m(2) portended a threefold risk of mortality. CONCLUSIONS: Our results suggest that specific components of right ventricular dysfunction and renal impairment contribute to increased mortality in SSc-PAH. Understanding the mechanisms of right ventricular dysfunction in response to increased afterload should lead to improved targeted therapy in these patients.
Authors: Gerald Simonneau; Nazzareno Galiè; Lewis J Rubin; David Langleben; Werner Seeger; Guido Domenighetti; Simon Gibbs; Didier Lebrec; Rudolf Speich; Maurice Beghetti; Stuart Rich; Alfred Fishman Journal: J Am Coll Cardiol Date: 2004-06-16 Impact factor: 24.094
Authors: Vallerie V McLaughlin; Kenneth W Presberg; Ramona L Doyle; Steven H Abman; Douglas C McCrory; Terry Fortin; Gregory Ahearn Journal: Chest Date: 2004-07 Impact factor: 9.410
Authors: Srijoy Mahapatra; Rick A Nishimura; Paul Sorajja; Stephen Cha; Michael D McGoon Journal: J Am Coll Cardiol Date: 2006-01-26 Impact factor: 24.094
Authors: D B Badesch; V F Tapson; M D McGoon; B H Brundage; L J Rubin; F M Wigley; S Rich; R J Barst; P S Barrett; K M Kral; M M Jöbsis; J E Loyd; S Murali; A Frost; R Girgis; R C Bourge; D D Ralph; C G Elliott; N S Hill; D Langleben; R J Schilz; V V McLaughlin; I M Robbins; B M Groves; S Shapiro; T A Medsger Journal: Ann Intern Med Date: 2000-03-21 Impact factor: 25.391
Authors: Grace L Smith; Judith H Lichtman; Michael B Bracken; Michael G Shlipak; Christopher O Phillips; Paul DiCapua; Harlan M Krumholz Journal: J Am Coll Cardiol Date: 2006-04-24 Impact factor: 24.094
Authors: Matthew R Lammi; Stephen C Mathai; Lesley Ann Saketkoo; Robyn T Domsic; Christine Bojanowski; Daniel E Furst; Virginia D Steen Journal: Arthritis Rheumatol Date: 2016-03 Impact factor: 10.995
Authors: Steven Hsu; Brian A Houston; Emmanouil Tampakakis; Anita C Bacher; Parker S Rhodes; Stephen C Mathai; Rachel L Damico; Todd M Kolb; Laura K Hummers; Ami A Shah; Zsuzsanna McMahan; Celia P Corona-Villalobos; Stefan L Zimmerman; Fredrick M Wigley; Paul M Hassoun; David A Kass; Ryan J Tedford Journal: Circulation Date: 2016-05-11 Impact factor: 29.690
Authors: Carlo Marini; Bruno Formichi; Carolina Bauleo; Claudio Michelassi; Edoardo Airò; Giuseppe Rossi; Carlo Giuntini Journal: Intern Emerg Med Date: 2016-04-06 Impact factor: 3.397
Authors: Daniel R Machin; Heather L Clifton; Ryan S Garten; Jayson R Gifford; Russell S Richardson; D Walter Wray; Tracy M Frech; Anthony J Donato Journal: Am J Physiol Heart Circ Physiol Date: 2016-09-30 Impact factor: 4.733